Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada has received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada’s investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 45 skipping.
Entrada is on track to initiate the ELEVATE-45-201 study in Q3 2025. ELEVATE-45 regulatory filings have been submitted in the European Union, with regulatory review ongoing.
Please read Entrada’s full press release here: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-receives-authorization-united-kingdom-1
If you would like to talk about the topic discussed in this article, please do reach out to us at info@actionduchenne.org.
Our Current Events: You can find links to our online support groups and information about how we can support schools with assemblies, workshops and staff training, and to register for our newly launched webinar series.
